NCT03964259View on ClinicalTrials.gov

Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 2, 2019

Primary Completion Date

December 7, 2022

Study Completion Date

December 28, 2022

Conditions
LymphomaAcute Lymphoblastic LeukemiaPediatric CancerPediatric ALLPediatric Lymphoma
Interventions
DRUG

Intravenous fluids

Administration of post HDMTX intravenous fluids (IVF)

Trial Locations (1)

23298

Virginia Commonwealth University/ Massey Cancer Center/ Children's Hospital of Richmond, Richmond

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER

NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter